Ence Chuck

RLMD CAO/COO Ence Chuck bought 136,000 shares at $2.20 (+50.8% of prior holdings); 3 other insiders also bought within 14 days

Ence Chuck, CAO and COO of Relmada Therapeutics, purchased 136,000 shares at $2.20 on 2025-11-05, expanding his holdings from 267,931 shares to 403,931 shares—a 50.8% increase. This transaction is part of a cluster buy pattern in which 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence at current valuations. His prior trades at RLMD show mixed near-term returns—two of four prior buys achieved positive 90-day returns (+55.2% and +34.5% respectively)—though the company faces fundamental headwinds: annualized revenue of $682.00 latest quarter, a net loss of $-9,866,442.00 over the most recent full year, and annual revenue growth of -35.4%. The stock has risen 31.2% in the past 30 days and 344.3% over 90 days from depressed levels, leaving it 25.2% below its 52-week high of $3.49. The timing and scale of this buy relative to both recent price momentum and underlying profitability decline warrants careful review.

Ence Chuck bought 228,961 shares of RLMD at $0.45 on 2025-05-16; stock now $0.60, -86.2% from 52-week high of $4.36.

Ence Chuck purchased 228,961 shares at $0.45, expanding his holdings by 587.5% to 267,931 shares total, in a company with severe fundamentals: annual revenue declined 35.4%, net income was negative $17,559,465, and market cap is only $19,914,973.20. The purchase price of $0.45 is well below the 52-week high of $4.36 (-86.2%), though the stock has rebounded 107.0% over the past 30 days and 82.9% over 90 days. His same-ticker buy history at RLMD shows mixed timing: of his 3 prior purchases at this ticker, only 1 of 3 registered positive 90-day returns (33.3% well-timed rate), with results ranging from +68.1% to -10.2% at the 90-day mark. A cluster pattern emerged with 3 other insiders also buying within the past 14 days, though this reflects coordinated rather than sole conviction.